ARTICLE | Clinical News
Lumiliximab: Suspended Phase II/III enrollment
October 26, 2009 7:00 AM UTC
Biogen Idec disclosed that it stopped recruitment in the Phase II/III LUCID trial of lumiliximab to treat CLL after a strategic review of the program determined that the trial would not support regist...